CTX-009(ABL001), a bispecific antibody targeting DLL4 and VEGF A, in combination with paclitaxel in patients with advanced biliary tract cancer (BTC): A Phase 2 study

Do-Youn Oh¹, Joon Oh Park², Jin Won Kim³, Kyu-Pyo Kim⁴, Jeesun Yoon¹, Tae-Yong Kim¹, Seung Tae Kim², Voung Suk Park², Jeeyun Lee², Ji-Won Kim³, Keun Wook Lee³, Baek-Yeol Ryoo⁴, Changhoon Yoo⁴, BokJin Hyun⁵, HyunJoo Son⁵, SunYoung Kim⁵, SangMi Lee⁶, Jooyeon Park⁶, Eunsin Ha⁶ ¹Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea; ²Division of Hematology-Oncology, Department of Medicine, Seoul, South Korea; ³Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul, South Korea; ⁶ABL Bio, Inc., Seongnam, South Korea; ⁶AB

Background

- CTX-009 is a novel bispecific antibody that simultaneously inhibits Delta-like ligand 4/Notch-1 (DLL4) and VEGF A, two signaling molecules which play an important role in angiogenesis in the tumor microenvironment.^{1, 2}
- Encouraging results in phase 1b in BTC pts, CTX-009 in combination with paclitaxel, including two durable Partial Responses (PRs) out of 3 pts, prompted the expansion of the study to a Phase 2 cohort which includes BTC pts treated in 2L or 3L setting. We present preliminary results of the Phase 2 study.

Methods


- This is a open-label, multi-center, single-arm Phase 2 study in pts with unresectable advanced, metastatic or recurrent BTC in 2L or 3L setting. Eligible pts were treated with CTX-009 (10 mg/kg IV biweekly) in combination with paclitaxel (80 mg/m² IV on Day 1, 8, 15 q4-weekly).
- The primary objective was to assess the objective response rate (ORR) based on RECIST v1.1. Secondary endpoints included time to treatment failure (TTF), duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety.

Results

• As of the data cut-off date (Nov 09, 2022), 24 pts have been enrolled and 1 pt remained on treatment. The median follow-up duration was 12.1 months (m; range, 1.6-19.1) and 11 pts were treated in 2L and 13 pts in 3L.

Table 1. Baseline characteristics

	Total (n = 24)			
Age (Years)				
Median (range)	61.5 (39-73)			
Sex, n (%)				
Male/Female	14 (58.3) / 10 (41.7)			
Time from diagnosis to randomization (year)				
Median (range)	2.2 (0.4-8.4)			
ECOG performance Status, n (%)				
0	13 (54.2)			
1	11 (45.8)			
Number of previous	systemic therapies, n (%)			
1	11 (45.8)			
2	13 (54.2)			
Previous therapy				
Surgery	18 (75.0)			
Radiotherapy	8 (33.3)			



BTC sub-type	n (2L/3L)
Intrahepatic cholangiocarcinoma	9 (4/5)
Extrahepatic cholangiocarcinoma	3 (1/2)
Gallbladder cancer	7 (4/3)
Ampullary carcinoma	5 (2/3)


• There were 9 confirmed PRs with ORR 37.5% (95% CI, 18.8-59.4; 2L: 63.6%, 3L: 15.4%) by investigator's assessment.

Table 2. Response rate

Response rate (n=24)	Investigator's assessment			
	Total (n=24)	2L (n=11)	3L (n=13)	
ORR	9 (37.5%)	7 (63.6%)	2 (15.4%)	
CR	0	0	0	
PR	9 (37.5%)	7 (63.6%)	2 (15.4%)	
SD	13 (54.2%)	4 (36.4%)	9 (69.2%)	
PD	0	0	0	
NE*	2 (8.3%)	0	2 (15.4%)	


* One participant with no post-baseline tumor scan and the other with tumor assessment scan before the scheduled first assessment. Objective response rate: ORR; Complete Response: CR; Partial Response: PR; Progressive Disease: PD; Not evaluable: NE

Figure 1. Waterfall plot of maximum change in tumor size by investigator's assessment (n=23)[†]



† One participant was not included due to absence of post-baseline tumor scan.

Figure 2. Swimmer plot by investigator's assessment (n=24)



• Median PFS and OS were 9.4 m (95% CI, 5.4-11.1) and 12.5 m (95% CI, 10.9-NA), respectively; the OS rate at 12 m was 52.4% (95% CI, 30.7-70.2). Median DOR was 6.9 m (95% CI, 3.5-NA) and median TTF 5.9 m (95% CI, 3.9-9.8).




Figure 3. Progression free survival (A) and Overall survival (B)

Contact information: ohdoyoun@snu.ac.kr

Safety

- TEAEs of \geq Grade (Gr) 3 were reported in 95.8% (including one grade 5 pneumonia), regardless of relationship to CTX-009 or paclitaxel. Six pts (25.0%) experienced TEAEs that led to discontinuation of the study treatment: confusional state, embolism, pneumonia, biliary fistula, large intestine perforation, blood creatinine increased, and blood urea nitrogen increased.
- The AEs of special interest (AESIs) were reported in 41.7% of pts and AESIs of \geq Gr 3 in 12.5% of pts.

Table 3. Adverse events

Overall AE, n (%) [case]**	CTX-009 +	CTX-009 + Paclitaxel		
Any TEAE (Treatment Emergent AE)	24 (100) [485]			
CTX-009 related AE	24 (100) [208]			
Serious AE	11 (45.8) [18]			
AE leading to discontinuation	6 (25.0) [8]			
TEAEs***, n (%) [case]**	Any Grade	Grade≥3		
Neutrophil count decreased	22 (91.7) [82]	20 (83.3) [58]		
Hypertension	12 (50.0) [27]	4 (16.7) [10]		
Platelet count decreased	9 (37.5) [28]	3 (12.5) [5]		
Anaemia	5 (20.8) [9]	5 (20.8) [8]		
Ascites	4 (16.7) [18]	2 (8.3) [12]		
Decreased appetite	4 (16.7) [8]	2 (8.3) [2]		
Neutropenia	2 (8.3) [8]	2 (8.3) [5]		
Liver abscess	2 (8.3) [7]	2 (8.3) [4]		
Hepatic infection	2 (8.3) [6]	2 (8.3) [3]		
Cholangitis	2 (8.3) [2]	2 (8.3) [2]		
Embolism	2 (8.3) [2]	2 (8.3) [2]		
AESIs, n (%) [case]**	Any Grade	Grade ≥3		
Haemoptysis or haemorrhage	10 (41.7) [21]	3 (12.5) [5]		
Pulmonary hypertension	4 (16.7) [4]	0 [0]		
GI or tumor perforation	2 (8.3) [3]	2(8.3) [2]		
Wound healing complication	0 [0]	0 [0]		
Cardiac failure	0 [0]	0 [0]		

** When Gr changed, the same AE was considered as separate cases and counted in duplicate. *** Only TEAEs with 2 or more adverse events with $Gr \ge 3$ were presented.

Conclusion

The Phase 2 study has shown promising efficacy in BTC pts treated in 2L or 3L setting. TRAEs based on mode of action was high, but DLL4/VEGF targeting in BTC has a potential of development. Further investigation of safety and efficacy of this regimen is warranted.

References and Acknowledgement

1. Kuhnert F, et al. Vasc Cell. 2011 Sep 18;3(1):20. 2. Li JL, et al. Cancer Res. 2011;71(18):6073-83.



